Panbela Therapeutics (NASDAQ:PBLA) Research Coverage Started at Roth Capital

Roth Capital initiated coverage on shares of Panbela Therapeutics (NASDAQ:PBLA – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a buy rating and a $10.00 target price on the stock.

Separately, Maxim Group cut shares of Panbela Therapeutics from a buy rating to a hold rating in a research report on Wednesday, October 12th.

Panbela Therapeutics Stock Performance

Panbela Therapeutics stock opened at $1.51 on Tuesday. Panbela Therapeutics has a 1 year low of $1.41 and a 1 year high of $96.00. The firm has a 50 day moving average price of $0.83 and a 200 day moving average price of $0.65. The company has a market cap of $1.19 million, a price-to-earnings ratio of -0.02 and a beta of 2.22.

Panbela Therapeutics (NASDAQ:PBLA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. acquired a new position in shares of Panbela Therapeutics during the third quarter worth $60,000. Armistice Capital LLC acquired a new position in shares of Panbela Therapeutics during the third quarter worth $588,000. UBS Group AG lifted its position in shares of Panbela Therapeutics by 46,589.5% during the third quarter. UBS Group AG now owns 190,493 shares of the company’s stock worth $51,000 after purchasing an additional 190,085 shares in the last quarter. Finally, Clear Street LLC acquired a new position in shares of Panbela Therapeutics during the third quarter worth $30,000. 9.37% of the stock is owned by institutional investors and hedge funds.

Panbela Therapeutics Company Profile

(Get Rating)

Panbela Therapeutics, Inc engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types.